Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. Close peer Versartis (VSAR) raised $126 million in its March IPO. Versartis...read more
Last week’s IPOs were up an average of 32% while the S&P 500 gained only 1%. Technology and health care companies (especially biotechs) continue to be the most active sectors of the IPO market, and last week they represented 19 of the 23 to price, set ...read more
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised $126 million by offering 6.0 million shares at $21, the high end of the revised $19 to $21 range. The company originally planned to offer 4.6 million shares at $16 to...read more
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more
Growth hormone biotech Ascendis Pharma files for a $86 million IPO
Ascendis Pharma, which is developing long-acting treatments for growth hormone deficiency, filed on Thursday with the SEC to raise up to $86 million in an initial public offering. Close peer Versartis (VSAR) raised $126 million in its March IPO. Versartis...read more
US IPO Recap: Year's largest biotech IPO Versartis jumps 49% amid tech-biotech frenzy
Last week’s IPOs were up an average of 32% while the S&P 500 gained only 1%. Technology and health care companies (especially biotechs) continue to be the most active sectors of the IPO market, and last week they represented 19 of the 23 to price, set ...read more
Versartis prices IPO at $21, the high end of the revised range
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised $126 million by offering 6.0 million shares at $21, the high end of the revised $19 to $21 range. The company originally planned to offer 4.6 million shares at $16 to...read more
Orphan disease biotech Versartis upsizes IPO and increases range to $19 to $21
Versartis, a biotech developing long-acting treatments for growth hormone deficiency, raised the proposed deal size for its upcoming IPO on Wednesday. The Redwood City, CA-based company now plans to raise up to $126 million by offering 6.0 million shares at a...read more